quinta-feira, 12 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 11, 2025

Shell plc announces Directorate changes

View original at finance.yahoo.com
Shell plc announces Directorate changes SHELL PLC BOARD AND COMMITTEE CHANGES December 11, 2025 Director Changes Shell plc (the Company) announces the following Board and Committee changes: Catherine Hughes, a Non-Executive Director and Chair of the Sustainability Committee, will not stand for re-election at the 2026 A…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Shell's Nomination and Succession Committee recommended Holly's and Clare's appointments to the Board following a thorough search process and review of their extensive, relevant experience and skills

    80% confidence
  • Catherine Hughes provided nine years of distinguished service to Shell, including her time as Chair of the Sustainability Committee, with deep industry expertise and strong track record of executing operational discipline

    80% confidence
  • Holly Koeppel is an experienced non-executive director who brings a wealth of international energy industry experience in both financial and operational leadership roles

    80% confidence
  • Clare Scherrer has extensive experience working with capital intensive global industrial companies, accelerating growth and increasing value

    80% confidence
  • Neil Carson made excellent contribution to Shell since joining the Board in 2019, including his time as Chair of the Remuneration Committee, bringing broad industrial outlook and commercial approach with practical perspectives on businesses

    80% confidence
  • Both Holly and Clare will make great contributions to the Shell Board

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,565 documentos-fonte arquivados
Consulte estes dados → isubstrate.com